NeuroSense regains compliance with NASDAQ listing rules

NeuroSense Therapeutics announced that it has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing. To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 6. NeuroSense’s CEO, Alon Ben-Noon said, “Regaining compliance with the Nasdaq minimum bid price listing requirement is an important event as we continue to focus on the advancement of PrimeC following the recently announced positive top-line results from the Phase 2b PARADIGM trial. We are looking forward to reporting results from our collaboration with Biogen in the coming weeks, evaluating the impact of PrimeC on neurofilament levels in participants enrolled in PARADIGM.”